876379-74-7 Usage
General Description
6-bromoH-pyrazolo[1,5-a]pyridine-2-carboxylic acid, also known as BPPA, is a chemical compound with the molecular formula C8H5BrN4O2. It is a heterocyclic aromatic compound that contains a pyrazolo[1,5-a]pyridine ring system with a carboxylic acid group attached at the 2-position and a bromine atom at the 6-position. 6-bromoH-pyrazolo[1,5-a]pyridine-2-carboxylic acid has shown potential as a building block for the synthesis of pharmaceutical compounds and as a ligand in coordination chemistry. It may also have applications in the development of new materials and as a research tool in organic synthesis and medicinal chemistry. Additionally, its unique structure and potential reactivity make it an interesting target for further study in the field of organic and pharmaceutical chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 876379-74-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,6,3,7 and 9 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 876379-74:
(8*8)+(7*7)+(6*6)+(5*3)+(4*7)+(3*9)+(2*7)+(1*4)=237
237 % 10 = 7
So 876379-74-7 is a valid CAS Registry Number.
InChI:InChI=1/C8H5BrN2O2/c9-5-1-2-6-3-7(8(12)13)10-11(6)4-5/h1-4H,(H,12,13)
876379-74-7Relevant articles and documents
TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME
-
Paragraph 00624, (2022/02/05)
The application relates to a compound of Formula (I) : or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of GLP-1 receptor, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which GLP-1 receptor plays a role.
METABOTROPIC GLUTAMATE RECEPTOR MODULATORS
-
Page/Page column 42, (2011/02/24)
The invention relates to heterocyclic derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders
